Comparing two mapping methods to guide ablation for repeated ventricular tachycardia
Compares two heart mapping methods guiding ablation in people with recurrent ventricular tachycardia.
Key facts
- Who runs it
- University of Arizona
- Where
- Phoenix, United StatesSee the site
- Trial code
- Registry title
- Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial
- Status
- Recruiting
- People taking part
- 360 people, planned
- Started
- 15 Apr 2025
- Expected to end
- 30 Apr 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Isochronal Late Activation Mapping (ILAM)
- High Density Voltage Mapping
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with repeated, sustained ventricular tachycardia (a fast, regular heart rhythm from the lower heart chambers) and scarred heart muscle. It compares two ways of mapping the heart to guide ablation (burning small areas of heart tissue).
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- At least one episode of sustained monomorphic VT (>30 sec) recorded by EGM or ECG in the 6 months before joining. Structural heart disease (ischemic or non-ischemic) with heart scar on echocardiography, CT or MRI, or ejection fraction <50% with scar, or arrhythmogenic RV cardiomyopathy/dysplasia. People with non-ischemic heart disease need a CT or MRI showing scar.
- Earlier treatment
- At least one anti-arrhythmic medicine (such as beta blocker, mexiletine, amiodarone or sotalol) did not work, was not tolerated, or was not wanted.
Main reasons for not taking part
- Pregnant or breastfeeding
- Left ventricular ejection fraction < 15%, or currently on ECMO or a ventricular assist device
- VT with no heart scar, VT from a reversible cause, or from channelopathies (LQTS, Brugada Syndrome)
- Stroke within 30 days, LV blood clot within 1 month, or heart surgery via sternotomy within 30 days
- Cannot take blood thinners, platelet count <50,000/μl, active infection, or life expectancy of 1 year or less
The registry criteria, word for word
Show all 25 criteriaShow less
Who cannot take part
- Cardiac surgery via sternotomy (CABG or valve repair/replacement) within 30 days prior to enrollment
- Contraindication to systemic anticoagulation (i.e., heparin, warfarin, or a direct thrombin inhibitor)
- Currently receiving support via extracorporeal membrane oxygenation (ECMO) or ventricular assist device (VAD)
- Stroke within 30 days or presence of LV thrombus within 1 month prior to enrollment
- Enrolled in an investigational study evaluating another device or drug that would confound the results of this study
- Active infection (positive blood culture)
- Ventricular tachycardia secondary to electrolyte imbalance or any other reversible or non-cardiac cause
- Ventricular arrhythmias secondary to underlying channelopathies (LQTS, Brugada Syndrome)
- Other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow up requirement of 1 year, or impact the scientific integrity of the study results
- Left Ventriclar ejection fraction < 15%
- Thrombocytopenia (defined as platelet count <50,000/μl ) or coagulopathy
- Subjects who meet any of the following exclusion criteria must be excluded from the clinical investigation:
- Patient is pregnant or nursing
- Idiopathic VT or preprocedural imaging without scar (MRI or CT)
- Limited life expectancy of 1 year or less
- Presence of mitral and aortic valves both mechanical
- Severe aortic stenosis or flail mitral valve with severed mitral regurgitation
Other criteria
- Criteria
- To participate in this clinical investigation, the subjects must meet all of the following inclusion criteria:
- Patient is ≥18 years of age
- Able and willing to comply with all study requirements
- At least one documented episode of sustained MMVT (>30 sec) by either EGM or ECG (including Holter, or loop recorder) in the 6 months prior to enrollment
- Informed of the nature of the study, agreed to its provisions, and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical study site
- Refractory (i.e., not effective, not tolerated, or not desired) to at least one anti-arrhythmic medication (including, but not limited to beta blocker, mexiletine, amiodarone or sotalol) for treatment of MMVT
- Structural heart disease (ischemic or non-ischemic) with one of the following (a, b or c):; Evidence of myocardial scar by echocardiography (segmental wall motion or wall thinning), CT (wall thinning) and/or MRI (presence of delayed enhancement /late gadolinium enhancement) . CT or MRI with scar is mandatory for inclusion of NICM., or; Left ventricular ejection fraction (EF) <50% [documented within the last 6 months via transthoracic echocardiogram (TTE), MRI] with presence of scar, or; Arrhythmogenic RV cardiomyopathy/dysplasia (per 2010 ARVC/D Task Force Criteria)
Where in United States
- Banner-University Medical Center PhoenixPhoenix, United StatesContact: Crystal Gonzalez, MSWTaking people
About the trial
What the trial wants to find out
This is a multicenter, prospective, parallel, randomized controlled trial to test for non-inferiority with an ILAM-guided VT ablation compared to conventional voltage- based ablation. The study has two treatment arms: conventional voltage mapping and ablation (control arm). In the investigational arm, the ablation strategy is guided by ILAM to target deceleration zones, blinded to voltage mapping. In the control arm, ablation will be performed to extensively ablate all low voltage regions (<1.5mV) during sinus rhythm, right ventricular (RV) pacing, or left ventricular (LV) pacing, with discretionary use of pacemapping and activation mapping. In both arms, mapping with be performed with a multielectrode catheter (HD Grid) and ablation will be performed using an irrigated tip catheter (FlexAbility SE or Tactiflex catheters).
Read full original descriptionShow less
In the control armonly voltage mapping displays will be utilized (blinded to functional ILAM and fractionation). High density mapping with automated last deflection annotation (Ensite X) will be performed in all patients randomized to ILAM approach during either sinus rhythm or RV pacing.
The 2 groups in the trial
- High Density Voltage MappingExisting treatment, for comparison
high-density voltage mapping will serve as the method to display the electroanatomic substrate for extensive and diffuse ablation within the low voltage area (\<1.5 mV)
- Isochronal Late Activation Mapping (ILAM)Treatment being tested
an isochronal late activation mapping (ILAM) display with automated last deflection annotation (EnSite X™) will be used to identify regions of isochronal crowding around a line of conduction block for targeted ablation therapy using a standard irrigated tip catheter (Flexability SE \& Tactiflex catheters).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial
- Plain-language title
- Comparing two mapping methods to guide ablation for repeated ventricular tachycardiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 July 2026